FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: November 30, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  SQUEGLIA ANTHONY DON
2. Date of Event Requiring Statement (Month/Day/Year)
12/03/2013
3. Issuer Name and Ticker or Trading Symbol
Boston Therapeutics, Inc. [BTHE]
(Last)
(First)
(Middle)
C/O BOSTON THERAPEUTICS, INC., 1750 ELM STREET, SUITE 103
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Financial Officer
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

MANCHESTER, NH 03104
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 118,350 (1)
D
 
Common Stock 6,000 (1)
I
Owned by the Reporting Person's wife, Elizabeth Squeglia

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock options (right to buy)   (2) 11/07/2019 Common Stock 500,000 $ 0.5 D  
Warrant (right to buy) 04/05/2014 10/05/2018 Common Stock 50,000 $ 0.5 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
SQUEGLIA ANTHONY DON
C/O BOSTON THERAPEUTICS, INC.
1750 ELM STREET, SUITE 103
MANCHESTER, NH 03104
      Chief Financial Officer  

Signatures

Anthony Squeglia 04/04/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Reflects the number of shares of common stock of the Issuer beneficially owned by Mr. Squeglia at the time of the occurrence of the event triggering the filing of this Form 3.
(2) Reflects the number of derivative securities of the Issuer owned by Mr. Squeglia at the time of the occurrence of the event triggering the filing of this Form 3. Options to purchase 125,000 shares vested upon grant of the option in November 2012. The balance of the option vests in 6 quarterly installments of 62,500 shares each with the first installment vesting on December 31, 2012 and the final installment vesting on March 31, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.